Ensign Peak Advisors’s CRISPR Therapeutics CRSP Stock Holding History

Ensign Peak Advisors’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$254K	Sell	4,664 -650	-12%	-$34.3K	﹤0.01%	1253
2026 Q1	$253K	Hold	5,314	–	–	﹤0.01%	1200
2025 Q4	$279K	Sell	5,314 -10,150	-66%	-$608K	﹤0.01%	1150
2025 Q3	$1M	Sell	15,464 -13,000	-46%	-$746K	﹤0.01%	1035
2025 Q2	$1.38M	Hold	28,464	–	–	﹤0.01%	1065
2025 Q1	$969K	Hold	28,464	–	–	﹤0.01%	1266
2024 Q4	$1.12M	Hold	28,464	–	–	﹤0.01%	1252
2024 Q3	$1.34M	Hold	28,464	–	–	﹤0.01%	1150
2024 Q2	$1.54M	Hold	28,464	–	–	﹤0.01%	1025
2024 Q1	$1.94M	Sell	28,464 -1,436	-5%	-$103K	﹤0.01%	943
2023 Q4	$1.87M	Hold	29,900	–	–	﹤0.01%	944
2023 Q3	$1.36M	Hold	29,900	–	–	﹤0.01%	990
2023 Q2	$1.68M	Buy	29,900 +2,200	+8%	+$125K	﹤0.01%	945
2023 Q1	$1.25M	Buy	+27,700	New	+$1.35M	﹤0.01%	1069
2022 Q3	–	Sell	-37,169	Closed	-$2.26M	–	2315
2022 Q2	$2.26M	Buy	+37,169	New	+$2.19M	0.01%	758

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

GSK plc London $602M AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

SOCM

SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Ensign Peak Advisors's CRSP Position: Q2 2026 in Review

Ensign Peak Advisors reduced its CRISPR Therapeutics (CRSP) stake by 12% in Q2 2026, selling an estimated $34.3K and leaving 4,664 shares worth $254K. The position accounts for ﹤0.01% of the portfolio, ranked #1253.

Ensign Peak Advisors first reported a position in CRSP in Q2 2022 and has held it in 15 quarters since. The position peaked at $2.26M in Q2 2022. 521 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

Ensign Peak Advisors held 4,664 shares of CRISPR Therapeutics worth $254K as of Q2 2026.
Ensign Peak Advisors sold 650 CRISPR Therapeutics shares in Q2 2026, an estimated $34.3K.
CRISPR Therapeutics made up ﹤0.01% of Ensign Peak Advisors's portfolio in Q2 2026, its #1253 holding.
Ensign Peak Advisors first reported a position in CRISPR Therapeutics in Q2 2022 and has held it in 15 quarters since.
Ensign Peak Advisors's CRISPR Therapeutics position peaked at $2.26M in Q2 2022.
521 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Ensign Peak Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.